Selim M, Foster L, Moy C, Xi G, Hill M, Morgenstern L, Greenberg S, James M, Singh V, Clark W, Norton C, Palesch Y, Yeatts S, Investigators I, Dolan M, Yeh E, Sheth K, Kunze K, Muehlschlegel S, Nieto I, Claassen J, Falo C, Huang D, Beckwith A, Messe S, Yates M, O'Phelan K, Escobar A, Becker K, Tanzi P, Gonzales N, Tremont C, Venkatasubramanian C, Thiessen R, Save S, Verrault S, Collard K, DeGeorgia M, Cwiklinski V, Thompson B, Wasilewski L, Andrews C, Burfeind R, Torbey M, Hamed M, Butcher K, Sivakumar L, Varelas N, Mays-Wilson K, Leira E, Olalde H, Silliman S, Calhoun R, Dangayach N, Renvill R, Malhotra R, Kordesch K, Lord A, Calahan T, Geocadin R, Parish M, Frey J, Harrigan M, Leifer D, Mathias R, Schneck M, Bernier T, Gonzales-Arias S, Elysee J, Lopez G, Volgi J, Brown R, Jasak S, Phillips S, Jarrett J, Gomes J, McBride M, Aldrich F, Aldrich C, Kornbluth J, Bettle M, Goldstein J, Tirrell G, Shaw Q, Jonczak K. Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. The Lancet Neurology 2019, 18: 428-438. PMID: 30898550, PMCID: PMC6494117, DOI: 10.1016/s1474-4422(19)30069-9.Peer-Reviewed Original Research